New products will grow atopic dermatitis market to $5.6 billion by 2022

Atopic dermatitis therapeutic sales in nine major global markets are forecast to increase from $3.9 billion in 2012 to $5.6 billion by 2022 according to research and consulting firm GlobalData.

The firm says the markets in the USA, France, Germany, Italy, Spain, UK, Japan, China and India will expand at a compound annual growth rate (CAGR) of 3.8%. According to the company’s latest report, the anticipated launch of new drugs by French drug major Sanofi (Euronext: SAN)/Regeneron and Anacor Pharmaceuticals (Nasdaq: ANAC) in the mid-term of the forecast period will bring a major boost to the market. Japan will also play a key role in driving global sales, while emerging markets India and China will experience rapid uptake of topical calcineurin inhibitors.

Tina Healy, GlobalData’s director for immunology, said: “Although both companies are expected to enter the atopic dermatitis space in 2016, Sanofi/Regeneron displays the greatest commercial prospects, as its pipeline candidate, dupilumab, is touted as a potential breakthrough therapy for moderate to severe disease. This stems from its potential to either compete with or displace gold-standard systemic agent cyclosporine. This in turn could address the high unmet need for an effective systemic drug for severe refractory disease.”